Risk factor
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of PHO.OL is 84 and suggests 27% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell